MedTrace Logo

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

NCT00468611 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2009-08-13

No results posted yet for this study

Summary

This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)

Conditions

  • Multiple Sclerosis, Secondary Progressive

Interventions

DRUG

MBP8298

500mg MBP8298 IV every six months for a period of two years

Sponsors & Collaborators

  • BioMS Technology Corp.

    lead INDUSTRY

Principal Investigators

  • Clyde E Markowitz, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-07-31
Completion
2009-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468611 on ClinicalTrials.gov